With diet and exercise, it is approved to improve blood sugar control in adults and children aged 10 and older with type 2 diabetes. It is also approved to reduce the risk of heart attack, stroke and cardiovascular death in adults with type 2 diabetes who have heart disease or several cardiovascular risk factors. It is not approved for weight loss.1
How the molecule is built
Dulaglutide takes a different route to a long half-life from semaglutide and liraglutide, which bind to albumin through a fatty acid. It is a fusion protein: two identical chains, each with a GLP-1 analog at one end joined by a short linker to the Fc portion of a modified human antibody, immunoglobulin G4. It is made in Chinese hamster ovary cell culture, and its GLP-1 part is 90% similar to human GLP-1, with changes that protect it from the enzyme DPP-4.1
The result is a half-life of about 5 days. At steady state the level peaks 24 to 72 hours after an injection, with a median of 48 hours.1 That is close to tirzepatide's half-life of about 5 days and shorter than semaglutide's of about 1 week.2,3
How the dose climbs
For adults Trulicity starts at 0.75 mg once a week. After 4 weeks it may go to 1.5 mg, and if more blood sugar control is needed it rises in steps of 1.5 mg, each after at least 4 weeks, to a maximum of 4.5 mg. For children aged 10 and older the maximum is 1.5 mg.1 Our page on timing a weekly GLP-1 shot covers changing the day and missed doses across the weekly medicines.
The REWIND heart trial
REWIND enrolled 9,901 adults with type 2 diabetes and either established cardiovascular disease or several cardiovascular risk factors, and followed them for a median of 5.4 years on Trulicity 1.5 mg or placebo, added to usual care.1
- A first heart attack, stroke or cardiovascular death occurred in 12.0% on Trulicity and 13.4% on placebo, a hazard ratio of 0.88.
- Non-fatal stroke occurred in 2.7% against 3.5%, a hazard ratio of 0.76.
- Cardiovascular death occurred in 6.4% against 7.0%, and non-fatal heart attack in 4.1% against 4.3%.
The labels describe LEADER and the Ozempic heart trial as trials in adults with atherosclerotic cardiovascular disease. REWIND also took people with risk factors alone, and the Trulicity heart indication covers both groups.1,2,4
Side effects and warnings
In the pooled placebo-controlled trials, nausea was reported by 12.4% on 0.75 mg and 21.1% on 1.5 mg, against 5.3% on placebo. Diarrhea was reported by 8.9% and 12.6% against 6.7%, and vomiting by 6.0% and 12.7% against 2.3%.1 In the trial of the higher doses, nausea was reported by 13.4% on 1.5 mg, 15.6% on 3 mg and 16.4% on 4.5 mg.1
Trulicity carries the boxed warning about thyroid C-cell tumors seen in rats and must not be used by people with a personal or family history of medullary thyroid carcinoma or with multiple endocrine neoplasia syndrome type 2.1 Our page on nausea on a GLP-1 covers what helps.
Dulaglutide in eight lines
| Fact | Trulicity |
|---|---|
| Active ingredient | Dulaglutide |
| Maker | Eli Lilly |
| First U.S. approval | 2014 |
| How often | Once a week, under the skin |
| Doses | 0.75 mg to start, up to 4.5 mg |
| Half-life | About 5 days |
| Built as | GLP-1 analog fused to an antibody fragment |
| Approved for weight loss | No |
TRULICITY prescribing information, DailyMed version of August 10, 2026.1
Related terms
Liraglutide and semaglutide are the GLP-1 receptor agonists built on albumin binding; tirzepatide, from the same maker as dulaglutide, adds a second receptor. Our page on Ozempic and Mounjaro compares the two most used weekly diabetes injections.
Sources
- TRULICITY (dulaglutide) injection prescribing information. Eli Lilly and Company; DailyMed, U.S. National Library of Medicine, version published August 10, 2026; boxed warning and sections 1, 2, 6.1, 11, 12 and 14. dailymed.nlm.nih.gov
- OZEMPIC (semaglutide) injection prescribing information, NDA 209637/S-039, revised May 2026. U.S. Food and Drug Administration; sections 12.3 and 14.2. accessdata.fda.gov
- MOUNJARO (tirzepatide) prescribing information, NDA 215866/S-052, revised April 2026. U.S. Food and Drug Administration; section 12.3. accessdata.fda.gov
- VICTOZA (liraglutide) injection prescribing information. Novo Nordisk; DailyMed, U.S. National Library of Medicine, version published November 17, 2025; section 14. dailymed.nlm.nih.gov
Related analyses
Ozempic vs Mounjaro: what the head-to-head trial and the two labels show
When to take your GLP-1 shot: time of day, changing the day and time zones
Ozempic side effects: how common each one is by dose, and when they ease
Nausea on a GLP-1: how common, how long, when it peaks and what helps
Log each weekly dose and see your week, levels and symptoms together.
Open Dose Insider